polyclonal use of t-cell receptor alpha for human t-cell lymphotropic virus type 1-infected t cells.

NLM AIDSLINE Polyclonal use of T-cell receptor alpha for human T-cell lymphotropic virus type 1-infected T cells. Masuoka K; Sagawa K; Mochizuki M; Oizumi K; Itoh K; Department of
April 30, 1995

Invest Ophthalmol Vis Sci. 1995 Jan;36(1):254-8. Unique Identifier : PURPOSE. To understand better the immunopathology of HTLV-I uveitis by investigating the clonality of HTLV-I-infected T-cell clones. METHODS. Eleven T-cell clones were established from the aqueous humor (six clones) and the peripheral blood (five clones) of a patient with HTLV-I uveitis, and the clonality of the HTLV-I-infected T cells was investigated by sequencing the T-cell receptor (TCR) alpha gene after the amplification of TCR alpha cDNA using an adaptor-ligation method and reverse transcriptase-polymerase chain reaction (RT-PCR). RESULTS. TCR alpha use was different for each of 11 T-cell clones, encompassing eight different HTLV-I-infected T-cell clones (four from the aqueous humor and four from peripheral blood) and three HTLV-I-negative T-cell clones. CONCLUSIONS. This study demonstrated polyclonal use of TCR alpha for HTLV-I-infected T cells in the ocular lesion and the peripheral blood. Results suggested that these T cells are not precursors of the leukemic cells associated with malignant transformation. Instead, they might be randomly infected with HTLV-I in the process of HTLV-I uveitis. Amino Acid Sequence Base Sequence Clone Cells DNA/ANALYSIS Human HTLV-I/PHYSIOLOGY HTLV-I Infections/IMMUNOLOGY Molecular Sequence Data Polymerase Chain Reaction Receptors, Antigen, T-Cell, alpha-beta/GENETICS/IMMUNOLOGY Support, Non-U.S. Gov't T-Lymphocytes/*VIROLOGY Uveitis/IMMUNOLOGY/VIROLOGY JOURNAL ARTICLE

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Photographs from A Day with HIV Now Online Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 ARIZONA: Routine Skin Testing Available Again at Tuberculosis Clinic Starting May 20 NORTH DAKOTA: Officials: 26 Tuberculosis Cases from Grand Forks Outbreak AUSTRALIA: HIV Rates Triple in the Northern Territory in Just 12 Months ARIZONA: Parsons Foundation Gives $3 Million to Southwest Center for HIV/AIDS UNITED STATES: Triple Therapy for Hepatitis C is Effective After Liver Transplantation, but Side-Effects Are Common CANADA: Nunavut Uses Comic Book to Do Sex Education NEW HAMPSHIRE: State Health Officials Urge Hepatitis Testing UNITED STATES: Hepatitis C Testing for People Born Between 1945 and 1965 People with HIV pay more for life insurance – if they can get it (South Africa)Uganda: Gov't Urged to Levy a Tax On Alcohol to Fund HIV CANADA: Nunavut Uses Comic Book to Do Sex Education PENNSYLVANIA: Scientists Weaken HIV Infection in Immune Cells Using Synthetic Agents HIV-infected teacher's aide accused of molestation Sangamo BioSciences Presents Clinical Data Demonstrating HIV Reservoir Reduction in HIV-Infected Subjects Treated with ZFP Therapeutic(R), SB-728-T Antiretroviral regimen associated with less virological failure among HIV-infected children 2012 US medicine sales show shifts by drug type Study Results from Eunice Kennedy Shriver National Institute of Child Health and Human Development Provide New Insights into HIV/AIDS AFRICA: Less-Used HIV Treatment for African Children More Effective Monetising Human Waste and 101 (Slightly) Crazy Other Ideas Less-used drug better treats HIV in kids: study
Information in this article was accurate in April 30, 1995. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.